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Abstract
Background: Epidermal nevi (EN) represent benign congenital skin lesions following the lines of Blaschko. They
result from genetic mosaicism, and activating FGFR3 and PIK3CA mutations have been implicated.
Case presentation: We report a female patient with a systemic keratinocytic nevus also involving the oral mucosa.
Molecular genetic analysis revealed a mosaicism of the FGFR3 hotspot mutation R248C in the EN lesions of the skin
and of the oral mucosa. The detection of the R248C mutation in a proportion of blood leukocytes and a slight
scoliosis suggest an EN syndrome.
Conclusions: Our results show that activating FGFR3 mutations can also affect the oral mucosa and that
extracutaneous manifestations of EN syndrome can be subtle. We highlight the theoretical risk of the patient
having an offspring with thanatophoric dysplasia as gonadal mosaicism for the R248C mutation cannot be
excluded.
Background
Epidermal nevi (EN) are benign hamartomas of the skin
arising from the embryonic ectoderm. Depending on the
involved components of the epidermis, EN are further
divided into organoid and non-organoid (keratinocytic)
types [1]. They are usually present at birth or develop
during the first years of life, and their incidence is esti-
mated to be 1-3 per 1000 live births [2]. Keratinocytic
nevi typically follow the lines of Blaschko. Systemic
keratinocytic nevi are characterized by an extensive
involvement of large skin areas and may be associated
with skeletal, cerebral or ocular abnormalities, resulting
in various types of EN syndromes [1,2]. EN represent
genetic mosaicism of the skin and activating FGFR3
(Fibroblast Growth Factor Receptor 3) and PIK3CA
point mutations have recently been identified in kerati-
nocytic nevi [3-6].
We report a patient with systemic EN associated with a
slight scoliosis, who displayed mosaicism of the R248C
FGFR3 mutation in epidermis, oral mucosa and blood
leukocytes.
Case presentation
A 17-year old girl was referred with widespread EN
(Figure 1 A+B). She was otherwise healthy apart from a
tendency to back pain. Her parents recalled the first
appearance of the EN when she was 4 months old. The
EN initially presented as hyperpigmented linear streaks
which gradually increased in size and thickness, becom-
ing more elevated and verrucous. The brown, papilloma-
tous and velvety EN followed the lines of Blaschko, with
streaks and whorls on her body stopping abruptly at the
ventral midline. The EN extended to her neck, scalp
and extremities and was present on her face (Figure 2).
She had intraoral mammilated lesions inside her lower
lip (Figure 3) and at the buccal mucosa close to her oral
angles. Laterally at the hard palate she had cobblestone-
like thickening of the mucosa. She did not show any
dysmorphic features and her face, trunk and extremities
appeared symmetric with normal proportions, although
a radiologic examination of the spine revealed a minimal
thoracic scoliosis of 5 degrees. An eye examination was
unremarkable and neurological examination was normal.
After informed consent of the patient and her parents,
a 4 mm punch biopsy was taken from the chest. On his-
tological examination, the biopsy showed a slightly
papillomatous surface with non-specific laminated
hyperkeratosis and acanthosis, typical of EN.
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The patient was diagnosed with a bilateral, systemic
keratinocytic nevus of the non-epidermolytic subtype.
Maceration in the intertriginous areas was troublesome,
but repeated laser (carbondioxide and Nd:YAG) treat-
ments were without great success, as the skin lesions
either relapsed or formed disfiguring scars.
Genetic analysis
Skin biopsies were taken from the EN on the abdomen
and from adjacent normal skin after informed consent of
the patient according to the guidelines of the local ethics
committee and the Declaration of Helsinki. Separate fibro-
blast cultures were established from these biopsies. DNA
was extracted directly from the skin biopsies as well as
from cultured fibroblasts. In addition, formalin-fixed par-
affin-embedded biopsy material, blood leukocytes, buccal
brushings from lesional mucosa, scalp hair roots, and
urothelial cells from urine sediment were available for ana-
lysis (Table 1). DNA was extracted from these tissues and
cells using standard protocols. FGFR3 and PIK3CA muta-
tions were analyzed using SNaPshot® assays as described
previously [6,7]. We identified the FGFR3 hotspot muta-
tion R248C in EN tissue, but not in the adjacent normal
skin (Figure 4). The R248C mutation was also detected in
the EN tissue of the buccal mucosa harvested by buccal
brushings. In contrast, the R248C mutation was not found
in cultured fibroblasts from either affected or normal skin,
nor in hair roots from affected skin of the scalp or in the
urothelial cells. No mutations in the PIK3CA gene were
found in any of the tissue samples.
Immunohistochemical staining of the EN tissue with
FGFR3 antibody (Santa Cruz Biotechnology, Santa Cruz,
USA) revealed expression of FGFR3 protein in the com-
plete epidermal layer, but the staining intensity was com-
parable with a normal skin control.
The results indicate that the systemic keratinocytic
nevus syndrome in the present patient is caused by
mosaicism of the R248C FGFR3 mutation. This mosai-
cism has extended to the oral mucosa, and caused
intraoral lesions. The genetic mosaicism can be limited
to the epidermis, but may also extend to other tissues,
resulting in EN syndromes [1,2]. The proportion of EN
(A) (B)
Figure 1 17-year old woman with an extensive, systemic epidermal nevus following the lines of Blaschko.
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patients with additional abnormalities of other organ sys-
tems is not known, and may vary depending on the dif-
ferent subtypes of EN. One comprehensive study
identified an EN syndrome in 33% of 119 EN patients [8].
In keratinocytic nevi, activating point mutations in
FGFR3 and PIK3CA genes have been identified in about
40% of patients [5,6]. Interestingly, the mutational
spectrum is restricted to hotspots, including R248C for
FGFR3 and E545G for PIK3CA. The same mutations
have been identified in sporadic malignant tumors, and
confer oncogenic properties to cells in vitro [9,10]. A
non-mosaic constitutional R248C FGFR3 mutation
causes thanatophoric dysplasia, a typically lethal skeletal
dysplasia [11]. Obviously, surviving patients with the
R248C FGFR3 mutation must be mosaics [12].
FGFR3 and PIK3CA mutations have also been identi-
fied in seborrheic keratoses which are benign epidermal
skin tumors arising in adult patients with an increasing
age-related incidence [5,13-15]. Although the identified
FGFR3 and PIK3CA mutations are oncogenic [10,16,17]
and can activate downstream signalling pathways
[18,19], neither EN nor seborrheic keratoses bear a sig-
nificant risk of malignant transformation.
In the patient of this case report, the R248C FGFR3
hotspot mutation was identified in the EN tissue of the
skin and buccal mucosa (ectoderm) as well as a substan-
tial proportion of blood leukocytes (mesoderm). With
the involvement of two embryologic tissues, one might
conclude that the mutation had happened at a very
early stage, in a cell whose descendant population
included skin and hematogenous precursor cells. The
early occurrence of the mutation might be the reason
for the widespread skin involvement.
To the best of our knowledge, we could show for the
first time that the mosaic FGFR3 mutation can be asso-
ciated with intraoral EN lesions, an otherwise uncommon
observation [20]. The wildtype sequence of unaffected
skin, hair roots and cultured fibroblasts in our patient
confirms that the R248C mutation occurred in a mosaic
form restricted to the epithelium and absent from the
stromal component of skin. We propose that this case
represents an EN syndrome, given the presence of the
mutation in blood leukocytes indicating bone marrow
involvement. Even her slight scoliosis may be part of the
Table 1 Results of genetic analysis
Sample Localization FGFR3 PIK3CA
1 EN Trunk R248C wt
2 EN Trunk R248C wt
3 Adjacent normal skin Trunk wt wt
4 Cultured fibroblasts (EN tissue) Trunk wt wt
5 Cultured fibroblasts (normal skin) Trunk wt wt
6 Hair roots Scalp wt na
7 Intraoral EN Buccal mucosa R248C na
8 Urothelial cells Urine
sediment
wt na
9 Leukocytes Blood R248C/
wt
wt
EN, epidermal nevus; FGFR3, Fibroblast Growth Factor Receptor 3; PIK3CA,
Phosphatidylinositol 3-kinase Catalytic 110 kD Alpha subunit; wt, wildtype; na,
not available.
Figure 2 Facial and neck involvement of epidermal nevus.
Figure 3 Mucosal involvement of epidermal nevus.
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syndrome, although the finding could be coincidental and
independent from the mosaicism. Hitherto the R248C
FGFR3 mutation has been identified in two cases of an
EN syndrome: - one with facial dysmorphism, and the
other patient with cerebral involvement [21,22]. A preli-
minary designation of “FGFR3 EN syndrome” has been
proposed, while acknowledging that a genetic heteroge-
neity may underlie the clinical phenotype of this syn-
drome [1,22]. For patients with extensive EN, a work-up
for EN syndrome is indicated even without obvious
extracutaneous features, as in our case.
Furthermore, it is important to be aware that these
patients may have a predisposition towards malignancies
of internal organs, especially low grade urothelial carci-
nomas [23-25]. As yet, there has been no report identify-
ing FGFR3 mutations in a patient with EN associated
with urothelial cancer or other malignancies [26]. How-
ever, FGFR3 mutations are involved in the pathogenesis
of bladder tumors, cervix carcinoma, and multiple mye-
loma [9,27]. The risk for the present patient is difficult to
assess, although the absence of the FGFR3 mutation in
urothelial cells suggests that at least for bladder cancer, it
may be low. The risk for malignant transformation of an
EN lesion (e.g., basal cell carcinoma or squamous cell
carcinoma) appears likewise to be low, although occa-
sional incidences have been reported [28-30].
If the FGFR3 mosaicism involves the gonad, our
patient is at risk of having offspring with thanatophoric
dysplasia. There is precedent for this, in a female patient
with extensive mosaicism of the R248C FGFR3 muta-
tion, including widespread acanthosis nigricans of the
skin and skeletal dysplasia [31].
Conclusions
We show that a mosaicism of the R248C FGFR3 muta-
tion can cause a systemic EN with involvement of the
oral mucosa. For patients with extensive EN, a work-up
for “EN syndrome” is indicated, as extracutaneous mani-
festations of the EN syndrome can be subtle. As gonadal
mosaicism for the R248C FGFR3 mutation cannot be
entirely excluded, a risk of having offspring with thana-
tophoric dysplasia exists. Prenatal diagnosis for the
R248C mutation will therefore be offered in future preg-
nancies of our patient.
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Figure 4 Genetic analysis of the FGFR3 gene by a SNaPshot® assay in various tissues revealed a mosaicism of the R248C hotspot
mutation.
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